Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma

This is a Single-center, open, single-arm clinical study, the goal of which was to evaluate the safety and efficacy of APRIL-BAFF-Bicephali CAR-T in relapsed and refractory multiple myeloma.The study consisted of four processes: patient enrollment screening; pre-CAR T cell therapy (including leukocyte apheresis, CAR T cell preparation and chemotherapy); inpatient monitoring phase for CAR T cell transfusion; and long-term follow-up phase

Trial Details

NCT ID

NCT06132711

Phase

PHASE1 / PHASE2

Sponsor

Xuzhou Medical University

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

APRIL-BAFF-Bicephali CAR-T cells

Locations (sample)

Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

The set subject inclusion criteria include multiple documents of multiple myeloma, no effective treatment options (e. g. autologous or allogeneic s…
Age is 18\~70 years old;
Expected survival period of\>12 weeks;
Multiple myeloma was diagnosed by physical examination, pathological examination, laboratory examination and imaging;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →